FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 19:28:00 24/05/2024 BST | ||
| 15.61 EUR | -5.22% |
|
| Current month | -15.35% | ||
| 1 month | -15.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 15.61 | -5.22% |
| 23/05/24 | 16.47 | -1.96% |
| 22/05/24 | 16.8 | -0.06% |
| 21/05/24 | 16.81 | +4.09% |
| 20/05/24 | 16.15 | -1.34% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 07:28 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME72UJ |
| ISIN | DE000ME72UJ0 |
| Date issued | 17/01/2024 |
| Strike | 301.6 kr |
| Maturity | Unlimited |
| Parity | 2.42 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.89 € |
|---|---|
| Lowest since issue | 10.16 € |
| Spread | 0.33 € |
| Spread % | 2.08% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
586.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+33.94%
- Stock Market
- Certificates
- Certificat
